Nasdaq Turns Lower; Kezar Life Sciences Shares Jump
U.S. stocks pared gains midway through trading, with the Nasdaq Composite and SP 500 turning lower on Tuesday. The Dow traded up 0.16% to 31,490.02 while the NASDAQ fell 0.72% to 11,441.85. The SP also fell, dropping, 0.12% to 3,895.32. Also check this: U.S. Consumer Confidence And Other Macro Issues For Tuesday Leading and Lagging Sectors Energy shares jumped by 2.9% on Tuesday. Meanwhile, top gainers in the sector included Earthstone Energy, Inc. (NYSE: ESTE ), up 9% and North European Oil Royalty Trust (NYSE: NRT ) up 7%. In trading on Tuesday, consumer discretionary shares fell by 0.9%. Top Headline U.S. goods gap shrank to $104.3 billion in May versus a revised $106.7 billion in April, recording the lowest trade gap so far this year. Exports rose 1.2% to a record high, with imports declining 0.1%. Equities Trading UP Kezar Life Sciences, Inc. (NASDAQ: KZR ) shares shot up 72% to $9.92 after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib.
Nasdaq Turns Lower; Kezar Life Sciences Shares Jump
U.S. stocks pared gains midway through trading, with the Nasdaq Composite and SP 500 turning lower on Tuesday. The Dow traded up 0.16% to 31,490.02 while the NASDAQ fell 0.72% to 11,441.85. The SP also fell, dropping, 0.12% to 3,895.32. Also check this: U.S. Consumer Confidence And Other Macro Issues For Tuesday Leading and Lagging Sectors Energy shares jumped by 2.9% on Tuesday. Meanwhile, top gainers in the sector included Earthstone Energy, Inc. (NYSE: ESTE ), up 9% and North European Oil Royalty Trust (NYSE: NRT ) up 7%. In trading on Tuesday, consumer discretionary shares fell by 0.9%. Top Headline U.S. goods gap shrank to $104.3 billion in May versus a revised $106.7 billion in April, recording the lowest trade gap so far this year. Exports rose 1.2% to a record high, with imports declining 0.1%. Equities Trading UP Kezar Life Sciences, Inc. (NASDAQ: KZR ) shares shot up 72% to $9.92 after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib.